According to Latest Study, the global market for Peptide CDMO Pharmaceutical should grow from US$ million in 2023 to US$ million by 2030, with a CAGR of % for the period of 2024-2030.

China Peptide CDMO Pharmaceutical market should grow from US$ million in 2023 to US$ million by 2030, with a CAGR of % for the period of 2024-2030.

The United States Peptide CDMO Pharmaceutical market should grow from US$ million in 2023 to US$ million by 2030, with a CAGR of % for the period of 2024-2030.

In terms of type, Liquid-phase Peptide Synthesis（LPPS） segment holds a share about % in 2024 and will reach % in 2030; while in terms of application, Peptide Supplements has a share approximately % in 2023 and will grow at a CAGR % during 2024 and 2030.

The global key manufacturers of Peptide CDMO Pharmaceutical include Ambiopharm, Auspep, Bachem, Bcn Peptide, Cpc Scientific, Creative Peptides, Chinese Peptide, Csbio and Corden Pharma, etc. In 2022, the global top five players hold a share approximately % in terms of revenue.

This report aims to provide a comprehensive study of the global market for Peptide CDMO Pharmaceutical. Report Highlights:

(1) Global Peptide CDMO Pharmaceutical market size (value), history data from 2019-2023 and forecast data from 2024 to 2030.

(2) Global Peptide CDMO Pharmaceutical market competitive situation, revenue and market share, from 2019 to 2023.

(3) China Peptide CDMO Pharmaceutical market competitive situation, revenue and market share, from 2019 to 2023.

(4) Global Peptide CDMO Pharmaceutical segment by region (or country), key regions cover the United States, Europe, Japan, South Korea, Southeast Asia and India, etc.

(5) Global Peptide CDMO Pharmaceutical segment by type and by application and regional segment by type and by application.

(6) Peptide CDMO Pharmaceutical industry supply chain, upstream, midstream and downstream analysis.

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa

Market segment by type, covers

Liquid-phase Peptide Synthesis（LPPS）

Solid-phase Peptide Synthesis（SPPS）

Mixed Phase

Market segment by application, can be divided into

Peptide Supplements

Peptide Vaccines

Others

Market segment by players, this report covers

Ambiopharm

Auspep

Bachem

Bcn Peptide

Cpc Scientific

Creative Peptides

Chinese Peptide

Csbio

Corden Pharma

Polypeptide

Hybio Pharmaceutical

Peptide Institute

Pepscan

Almac

Vivitide

Creosalus Inc

Scinopharm

Senn Chemicals

Belyntic

Ferring Pharma

Numaferm

Hybio Pharmaceutical

Provepharm Life Solutions

Enzene Biosciences

Piramal Pharma

1 Market Overview

1.1 Product Overview and Scope of Peptide CDMO Pharmaceutical

1.2 Global Peptide CDMO Pharmaceutical Market Size and Forecast

1.3 China Peptide CDMO Pharmaceutical Market Size and Forecast

1.4 China Market Percentage in Global

1.4.1 By Revenue, China Peptide CDMO Pharmaceutical Share in Global Market, 2019-2030

1.4.2 Peptide CDMO Pharmaceutical Market Size: China VS Global, 2019-2030

1.5 Peptide CDMO Pharmaceutical Market Dynamics

1.5.1 Peptide CDMO Pharmaceutical Market Drivers

1.5.2 Peptide CDMO Pharmaceutical Market Restraints

1.5.3 Peptide CDMO Pharmaceutical Industry Trends

1.5.4 Peptide CDMO Pharmaceutical Industry Policy

2 Global Competitive Situation by Company

2.1 Global Peptide CDMO Pharmaceutical Revenue by Company (2019-2024)

2.2 Global Peptide CDMO Pharmaceutical Participants, Market Position (Tier 1, Tier 2 and Tier 3)

2.3 Global Peptide CDMO Pharmaceutical Concentration Ratio

2.4 Global Peptide CDMO Pharmaceutical Mergers & Acquisitions, Expansion Plans

2.5 Global Peptide CDMO Pharmaceutical Manufacturers Product Type

3 China Competitive Situation by Company

3.1 China Peptide CDMO Pharmaceutical Revenue by Company (2019-2024)

3.2 China Peptide CDMO Pharmaceutical Peptide CDMO Pharmaceutical Participants, Market Position (Tier 1, Tier 2 and Tier 3)

3.3 China Peptide CDMO Pharmaceutical, Revenue Percentage of Local Players VS Foreign Manufacturers (2019-2024)

4 Industry Chain Analysis

4.1 Peptide CDMO Pharmaceutical Industry Chain

4.2 Peptide CDMO Pharmaceutical Upstream Analysis

4.3 Peptide CDMO Pharmaceutical Midstream Analysis

4.4 Peptide CDMO Pharmaceutical Downstream Analysis

5 Sights by Type

5.1 Peptide CDMO Pharmaceutical Classification

5.1.1 Liquid-phase Peptide Synthesis（LPPS）

5.1.2 Solid-phase Peptide Synthesis（SPPS）

5.1.3 Mixed Phase

5.2 By Type, Global Peptide CDMO Pharmaceutical Market Size & CAGR, 2019 VS 2024 VS 2030

5.3 By Type, Global Peptide CDMO Pharmaceutical Revenue, 2019-2030

6 Sights by Application

6.1 Peptide CDMO Pharmaceutical Segment by Application

6.1.1 Peptide Supplements

6.1.2 Peptide Vaccines

6.1.3 Others

6.2 By Application, Global Peptide CDMO Pharmaceutical Market Size & CAGR, 2019 VS 2024 VS 2030

6.3 By Application, Global Peptide CDMO Pharmaceutical Revenue, 2019-2030

7 Sales Sights by Region

7.1 By Region, Global Peptide CDMO Pharmaceutical Market Size, 2019 VS 2024 VS 2030

7.2 By Region, Global Peptide CDMO Pharmaceutical Market Size, 2019-2030

7.3 North America

7.3.1 North America Peptide CDMO Pharmaceutical Market Size & Forecasts, 2019-2030

7.3.2 By Country, North America Peptide CDMO Pharmaceutical Market Size Market Share

7.4 Europe

7.4.1 Europe Peptide CDMO Pharmaceutical Market Size & Forecasts, 2019-2030

7.4.2 By Country, Europe Peptide CDMO Pharmaceutical Market Size Market Share

7.5 Asia Pacific

7.5.1 Asia Pacific Peptide CDMO Pharmaceutical Market Size & Forecasts, 2019-2030

7.5.2 By Country/Region, Asia Pacific Peptide CDMO Pharmaceutical Market Size Market Share

7.6 South America

7.6.1 South America Peptide CDMO Pharmaceutical Market Size & Forecasts, 2019-2030

7.6.2 By Country, South America Peptide CDMO Pharmaceutical Market Size Market Share

7.7 Middle East & Africa

8 Sights by Country Level

8.1 By Country, Global Peptide CDMO Pharmaceutical Market Size & CAGR，2019 VS 2024 VS 2030

8.2 By Country, Global Peptide CDMO Pharmaceutical Market Size, 2019-2030

8.3 U.S.

8.3.1 U.S. Peptide CDMO Pharmaceutical Market Size, 2019-2030

8.3.2 By Company, U.S. Peptide CDMO Pharmaceutical Revenue Market Share, 2019-2024

8.3.3 By Type, U.S. Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

8.3.4 By Application, U.S. Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

8.4 Europe

8.4.1 Europe Peptide CDMO Pharmaceutical Market Size, 2019-2030

8.4.2 By Company, Europe Peptide CDMO Pharmaceutical Revenue Market Share, 2019-2024

8.4.3 By Type, Europe Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

8.4.4 By Application, Europe Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

8.5 China

8.5.1 China Peptide CDMO Pharmaceutical Market Size, 2019-2030

8.5.2 By Company, China Peptide CDMO Pharmaceutical Revenue Market Share, 2019-2024

8.5.3 By Type, China Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

8.5.4 By Application, China Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

8.6 Japan

8.6.1 Japan Peptide CDMO Pharmaceutical Market Size, 2019-2030

8.6.2 By Company, Japan Peptide CDMO Pharmaceutical Revenue Market Share, 2019-2024

8.6.3 By Type, Japan Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

8.6.4 By Application, Japan Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

8.7 South Korea

8.7.1 South Korea Peptide CDMO Pharmaceutical Market Size, 2019-2030

8.7.2 By Company, South Korea Peptide CDMO Pharmaceutical Revenue Market Share, 2019-2024

8.7.3 By Type, South Korea Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

8.7.4 By Application, South Korea Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

8.8 Southeast Asia

8.8.1 Southeast Asia Peptide CDMO Pharmaceutical Market Size, 2019-2030

8.8.2 By Company, Southeast Asia Peptide CDMO Pharmaceutical Revenue Market Share, 2019-2024

8.8.3 By Type, Southeast Asia Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

8.8.4 By Application, Southeast Asia Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

8.9 India

8.9.1 India Peptide CDMO Pharmaceutical Market Size, 2019-2030

8.9.2 By Company, India Peptide CDMO Pharmaceutical Revenue Market Share, 2019-2024

8.9.3 By Type, India Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

8.9.4 By Application, India Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

8.10 Middle East & Asia

8.10.1 Middle East & Asia Peptide CDMO Pharmaceutical Market Size, 2019-2030

8.10.2 By Company, Middle East & Asia Peptide CDMO Pharmaceutical Revenue Market Share, 2019-2024

8.10.3 By Type, Middle East & Asia Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

8.10.4 By Application, Middle East & Asia Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

9 Global Manufacturers Profile

9.1 Ambiopharm

9.1.1 Ambiopharm Company Information, Head Office, Market Area and Industry Position

9.1.2 Ambiopharm Company Profile and Main Business

9.1.3 Ambiopharm Peptide CDMO Pharmaceutical Models, Specifications and Application

9.1.4 Ambiopharm Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.1.5 Ambiopharm Recent Developments

9.2 Auspep

9.2.1 Auspep Company Information, Head Office, Market Area and Industry Position

9.2.2 Auspep Company Profile and Main Business

9.2.3 Auspep Peptide CDMO Pharmaceutical Models, Specifications and Application

9.2.4 Auspep Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.2.5 Auspep Recent Developments

9.3 Bachem

9.3.1 Bachem Company Information, Head Office, Market Area and Industry Position

9.3.2 Bachem Company Profile and Main Business

9.3.3 Bachem Peptide CDMO Pharmaceutical Models, Specifications and Application

9.3.4 Bachem Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.3.5 Bachem Recent Developments

9.4 Bcn Peptide

9.4.1 Bcn Peptide Company Information, Head Office, Market Area and Industry Position

9.4.2 Bcn Peptide Company Profile and Main Business

9.4.3 Bcn Peptide Peptide CDMO Pharmaceutical Models, Specifications and Application

9.4.4 Bcn Peptide Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.4.5 Bcn Peptide Recent Developments

9.5 Cpc Scientific

9.5.1 Cpc Scientific Company Information, Head Office, Market Area and Industry Position

9.5.2 Cpc Scientific Company Profile and Main Business

9.5.3 Cpc Scientific Peptide CDMO Pharmaceutical Models, Specifications and Application

9.5.4 Cpc Scientific Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.5.5 Cpc Scientific Recent Developments

9.6 Creative Peptides

9.6.1 Creative Peptides Company Information, Head Office, Market Area and Industry Position

9.6.2 Creative Peptides Company Profile and Main Business

9.6.3 Creative Peptides Peptide CDMO Pharmaceutical Models, Specifications and Application

9.6.4 Creative Peptides Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.6.5 Creative Peptides Recent Developments

9.7 Chinese Peptide

9.7.1 Chinese Peptide Company Information, Head Office, Market Area and Industry Position

9.7.2 Chinese Peptide Company Profile and Main Business

9.7.3 Chinese Peptide Peptide CDMO Pharmaceutical Models, Specifications and Application

9.7.4 Chinese Peptide Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.7.5 Chinese Peptide Recent Developments

9.8 Csbio

9.8.1 Csbio Company Information, Head Office, Market Area and Industry Position

9.8.2 Csbio Company Profile and Main Business

9.8.3 Csbio Peptide CDMO Pharmaceutical Models, Specifications and Application

9.8.4 Csbio Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.8.5 Csbio Recent Developments

9.9 Corden Pharma

9.9.1 Corden Pharma Company Information, Head Office, Market Area and Industry Position

9.9.2 Corden Pharma Company Profile and Main Business

9.9.3 Corden Pharma Peptide CDMO Pharmaceutical Models, Specifications and Application

9.9.4 Corden Pharma Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.9.5 Corden Pharma Recent Developments

9.10 Polypeptide

9.10.1 Polypeptide Company Information, Head Office, Market Area and Industry Position

9.10.2 Polypeptide Company Profile and Main Business

9.10.3 Polypeptide Peptide CDMO Pharmaceutical Models, Specifications and Application

9.10.4 Polypeptide Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.10.5 Polypeptide Recent Developments

9.11 Hybio Pharmaceutical

9.11.1 Hybio Pharmaceutical Company Information, Head Office, Market Area and Industry Position

9.11.2 Hybio Pharmaceutical Company Profile and Main Business

9.11.3 Hybio Pharmaceutical Peptide CDMO Pharmaceutical Models, Specifications and Application

9.11.4 Hybio Pharmaceutical Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.11.5 Hybio Pharmaceutical Recent Developments

9.12 Peptide Institute

9.12.1 Peptide Institute Company Information, Head Office, Market Area and Industry Position

9.12.2 Peptide Institute Company Profile and Main Business

9.12.3 Peptide Institute Peptide CDMO Pharmaceutical Models, Specifications and Application

9.12.4 Peptide Institute Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.12.5 Peptide Institute Recent Developments

9.13 Pepscan

9.13.1 Pepscan Company Information, Head Office, Market Area and Industry Position

9.13.2 Pepscan Company Profile and Main Business

9.13.3 Pepscan Peptide CDMO Pharmaceutical Models, Specifications and Application

9.13.4 Pepscan Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.13.5 Pepscan Recent Developments

9.14 Almac

9.14.1 Almac Company Information, Head Office, Market Area and Industry Position

9.14.2 Almac Company Profile and Main Business

9.14.3 Almac Peptide CDMO Pharmaceutical Models, Specifications and Application

9.14.4 Almac Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.14.5 Almac Recent Developments

9.15 Vivitide

9.15.1 Vivitide Company Information, Head Office, Market Area and Industry Position

9.15.2 Vivitide Company Profile and Main Business

9.15.3 Vivitide Peptide CDMO Pharmaceutical Models, Specifications and Application

9.15.4 Vivitide Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.15.5 Vivitide Recent Developments

9.16 Creosalus Inc

9.16.1 Creosalus Inc Company Information, Head Office, Market Area and Industry Position

9.16.2 Creosalus Inc Company Profile and Main Business

9.16.3 Creosalus Inc Peptide CDMO Pharmaceutical Models, Specifications and Application

9.16.4 Creosalus Inc Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.16.5 Creosalus Inc Recent Developments

9.17 Scinopharm

9.17.1 Scinopharm Company Information, Head Office, Market Area and Industry Position

9.17.2 Scinopharm Company Profile and Main Business

9.17.3 Scinopharm Peptide CDMO Pharmaceutical Models, Specifications and Application

9.17.4 Scinopharm Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.17.5 Scinopharm Recent Developments

9.18 Senn Chemicals

9.18.1 Senn Chemicals Company Information, Head Office, Market Area and Industry Position

9.18.2 Senn Chemicals Company Profile and Main Business

9.18.3 Senn Chemicals Peptide CDMO Pharmaceutical Models, Specifications and Application

9.18.4 Senn Chemicals Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.18.5 Senn Chemicals Recent Developments

9.19 Belyntic

9.19.1 Belyntic Company Information, Head Office, Market Area and Industry Position

9.19.2 Belyntic Company Profile and Main Business

9.19.3 Belyntic Peptide CDMO Pharmaceutical Models, Specifications and Application

9.19.4 Belyntic Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.19.5 Belyntic Recent Developments

9.20 Ferring Pharma

9.20.1 Ferring Pharma Company Information, Head Office, Market Area and Industry Position

9.20.2 Ferring Pharma Company Profile and Main Business

9.20.3 Ferring Pharma Peptide CDMO Pharmaceutical Models, Specifications and Application

9.20.4 Ferring Pharma Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.20.5 Ferring Pharma Recent Developments

9.21 Numaferm

9.21.1 Numaferm Company Information, Head Office, Market Area and Industry Position

9.21.2 Numaferm Company Profile and Main Business

9.21.3 Numaferm Peptide CDMO Pharmaceutical Models, Specifications and Application

9.21.4 Numaferm Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.21.5 Numaferm Recent Developments

9.22 Hybio Pharmaceutical

9.22.1 Hybio Pharmaceutical Company Information, Head Office, Market Area and Industry Position

9.22.2 Hybio Pharmaceutical Company Profile and Main Business

9.22.3 Hybio Pharmaceutical Peptide CDMO Pharmaceutical Models, Specifications and Application

9.22.4 Hybio Pharmaceutical Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.22.5 Hybio Pharmaceutical Recent Developments

9.23 Provepharm Life Solutions

9.23.1 Provepharm Life Solutions Company Information, Head Office, Market Area and Industry Position

9.23.2 Provepharm Life Solutions Company Profile and Main Business

9.23.3 Provepharm Life Solutions Peptide CDMO Pharmaceutical Models, Specifications and Application

9.23.4 Provepharm Life Solutions Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.23.5 Provepharm Life Solutions Recent Developments

9.24 Enzene Biosciences

9.24.1 Enzene Biosciences Company Information, Head Office, Market Area and Industry Position

9.24.2 Enzene Biosciences Company Profile and Main Business

9.24.3 Enzene Biosciences Peptide CDMO Pharmaceutical Models, Specifications and Application

9.24.4 Enzene Biosciences Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.24.5 Enzene Biosciences Recent Developments

9.25 Piramal Pharma

9.25.1 Piramal Pharma Company Information, Head Office, Market Area and Industry Position

9.25.2 Piramal Pharma Company Profile and Main Business

9.25.3 Piramal Pharma Peptide CDMO Pharmaceutical Models, Specifications and Application

9.25.4 Piramal Pharma Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.25.5 Piramal Pharma Recent Developments

10 Conclusion

11 Appendix

11.1 Research Methodology

11.2 Data Source

11.2.1 Secondary Sources

11.2.2 Primary Sources

11.3 Market Estimation Model

11.4 Disclaimer

Table 1. Peptide CDMO Pharmaceutical Market Size & CAGR: China VS Global, (US$ Million), 2019-2030

Table 2. Peptide CDMO Pharmaceutical Market Restraints

Table 3. Peptide CDMO Pharmaceutical Market Trends

Table 4. Peptide CDMO Pharmaceutical Industry Policy

Table 5. Global Peptide CDMO Pharmaceutical Revenue by Company (2019-2024) & (US$ million)

Table 6. Global Peptide CDMO Pharmaceutical Revenue Market Share by Company (2019-2024)

Table 7. Global Peptide CDMO Pharmaceutical Manufacturers Market Concentration Ratio (CR3 and HHI)

Table 8. Global Peptide CDMO Pharmaceutical Mergers & Acquisitions, Expansion Plans

Table 9. Global Peptide CDMO Pharmaceutical Manufacturers Product Type

Table 10. China Peptide CDMO Pharmaceutical Revenue by Company (2019-2024) & (US$ million)

Table 11. China Peptide CDMO Pharmaceutical Revenue Market Share by Company (2019-2024)

Table 12. Global Key Players of Peptide CDMO Pharmaceutical Upstream (Raw Materials)

Table 13. Global Peptide CDMO Pharmaceutical Typical Customers

Table 14. Peptide CDMO Pharmaceutical Typical Distributors

Table 15. By Type, Global Peptide CDMO Pharmaceutical Revenue & CAGR, 2019 VS 2024 VS 2030, US$ Million

Table 16. By Application, Global Peptide CDMO Pharmaceutical Revenue & CAGR, 2019 VS 2024 VS 2030, US$ Million

Table 17. By Region, Global Peptide CDMO Pharmaceutical Market Size, 2019 VS 2024 VS 2030, US$ Million

Table 18. By Region, Global Peptide CDMO Pharmaceutical Revenue, 2019-2030, US$ Million

Table 19. By Country, Global Peptide CDMO Pharmaceutical Revenue & CAGR，2019 VS 2024 VS 2030, US$ Million

Table 20. By Country, Global Peptide CDMO Pharmaceutical Revenue, 2019-2030, US$ Million

Table 21. By Country, Global Peptide CDMO Pharmaceutical Revenue Market Share, 2019-2030

Table 22. Ambiopharm Company Information, Head Office, Market Area and Industry Position

Table 23. Ambiopharm Company Profile and Main Business

Table 24. Ambiopharm Peptide CDMO Pharmaceutical Models, Specifications and Application

Table 25. Ambiopharm Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

Table 26. Ambiopharm Recent Developments

Table 27. Auspep Company Information, Head Office, Market Area and Industry Position

Table 28. Auspep Company Profile and Main Business

Table 29. Auspep Peptide CDMO Pharmaceutical Models, Specifications and Application

Table 30. Auspep Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

Table 31. Auspep Recent Developments

Table 32. Bachem Company Information, Head Office, Market Area and Industry Position

Table 33. Bachem Company Profile and Main Business

Table 34. Bachem Peptide CDMO Pharmaceutical Models, Specifications and Application

Table 35. Bachem Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

Table 36. Bachem Recent Developments

Table 37. Bcn Peptide Company Information, Head Office, Market Area and Industry Position

Table 38. Bcn Peptide Company Profile and Main Business

Table 39. Bcn Peptide Peptide CDMO Pharmaceutical Models, Specifications and Application

Table 40. Bcn Peptide Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

Table 41. Bcn Peptide Recent Developments

Table 42. Cpc Scientific Company Information, Head Office, Market Area and Industry Position

Table 43. Cpc Scientific Company Profile and Main Business

Table 44. Cpc Scientific Peptide CDMO Pharmaceutical Models, Specifications and Application

Table 45. Cpc Scientific Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

Table 46. Cpc Scientific Recent Developments

Table 47. Creative Peptides Company Information, Head Office, Market Area and Industry Position

Table 48. Creative Peptides Company Profile and Main Business

Table 49. Creative Peptides Peptide CDMO Pharmaceutical Models, Specifications and Application

Table 50. Creative Peptides Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

Table 51. Creative Peptides Recent Developments

Table 52. Chinese Peptide Company Information, Head Office, Market Area and Industry Position

Table 53. Chinese Peptide Company Profile and Main Business

Table 54. Chinese Peptide Peptide CDMO Pharmaceutical Models, Specifications and Application

Table 55. Chinese Peptide Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

Table 56. Chinese Peptide Recent Developments

Table 57. Csbio Company Information, Head Office, Market Area and Industry Position

Table 58. Csbio Company Profile and Main Business

Table 59. Csbio Peptide CDMO Pharmaceutical Models, Specifications and Application

Table 60. Csbio Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

Table 61. Csbio Recent Developments

Table 62. Corden Pharma Company Information, Head Office, Market Area and Industry Position

Table 63. Corden Pharma Company Profile and Main Business

Table 64. Corden Pharma Peptide CDMO Pharmaceutical Models, Specifications and Application

Table 65. Corden Pharma Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

Table 66. Corden Pharma Recent Developments

Table 67. Polypeptide Company Information, Head Office, Market Area and Industry Position

Table 68. Polypeptide Company Profile and Main Business

Table 69. Polypeptide Peptide CDMO Pharmaceutical Models, Specifications and Application

Table 70. Polypeptide Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

Table 71. Polypeptide Recent Developments

Table 72. Hybio Pharmaceutical Company Information, Head Office, Market Area and Industry Position

Table 73. Hybio Pharmaceutical Company Profile and Main Business

Table 74. Hybio Pharmaceutical Peptide CDMO Pharmaceutical Models, Specifications and Application

Table 75. Hybio Pharmaceutical Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

Table 76. Hybio Pharmaceutical Recent Developments

Table 77. Peptide Institute Company Information, Head Office, Market Area and Industry Position

Table 78. Peptide Institute Company Profile and Main Business

Table 79. Peptide Institute Peptide CDMO Pharmaceutical Models, Specifications and Application

Table 80. Peptide Institute Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

Table 81. Peptide Institute Recent Developments

Table 82. Pepscan Company Information, Head Office, Market Area and Industry Position

Table 83. Pepscan Company Profile and Main Business

Table 84. Pepscan Peptide CDMO Pharmaceutical Models, Specifications and Application

Table 85. Pepscan Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

Table 86. Pepscan Recent Developments

Table 87. Almac Company Information, Head Office, Market Area and Industry Position

Table 88. Almac Company Profile and Main Business

Table 89. Almac Peptide CDMO Pharmaceutical Models, Specifications and Application

Table 90. Almac Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

Table 91. Almac Recent Developments

Table 92. Vivitide Company Information, Head Office, Market Area and Industry Position

Table 93. Vivitide Company Profile and Main Business

Table 94. Vivitide Peptide CDMO Pharmaceutical Models, Specifications and Application

Table 95. Vivitide Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

Table 96. Vivitide Recent Developments

Table 97. Creosalus Inc Company Information, Head Office, Market Area and Industry Position

Table 98. Creosalus Inc Company Profile and Main Business

Table 99. Creosalus Inc Peptide CDMO Pharmaceutical Models, Specifications and Application

Table 100. Creosalus Inc Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

Table 101. Creosalus Inc Recent Developments

Table 102. Scinopharm Company Information, Head Office, Market Area and Industry Position

Table 103. Scinopharm Company Profile and Main Business

Table 104. Scinopharm Peptide CDMO Pharmaceutical Models, Specifications and Application

Table 105. Scinopharm Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

Table 106. Scinopharm Recent Developments

Table 107. Senn Chemicals Company Information, Head Office, Market Area and Industry Position

Table 108. Senn Chemicals Company Profile and Main Business

Table 109. Senn Chemicals Peptide CDMO Pharmaceutical Models, Specifications and Application

Table 110. Senn Chemicals Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

Table 111. Senn Chemicals Recent Developments

Table 112. Belyntic Company Information, Head Office, Market Area and Industry Position

Table 113. Belyntic Company Profile and Main Business

Table 114. Belyntic Peptide CDMO Pharmaceutical Models, Specifications and Application

Table 115. Belyntic Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

Table 116. Belyntic Recent Developments

Table 117. Ferring Pharma Company Information, Head Office, Market Area and Industry Position

Table 118. Ferring Pharma Company Profile and Main Business

Table 119. Ferring Pharma Peptide CDMO Pharmaceutical Models, Specifications and Application

Table 120. Ferring Pharma Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

Table 121. Ferring Pharma Recent Developments

Table 122. Numaferm Company Information, Head Office, Market Area and Industry Position

Table 123. Numaferm Company Profile and Main Business

Table 124. Numaferm Peptide CDMO Pharmaceutical Models, Specifications and Application

Table 125. Numaferm Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

Table 126. Numaferm Recent Developments

Table 127. Hybio Pharmaceutical Company Information, Head Office, Market Area and Industry Position

Table 128. Hybio Pharmaceutical Company Profile and Main Business

Table 129. Hybio Pharmaceutical Peptide CDMO Pharmaceutical Models, Specifications and Application

Table 130. Hybio Pharmaceutical Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

Table 131. Hybio Pharmaceutical Recent Developments

Table 132. Provepharm Life Solutions Company Information, Head Office, Market Area and Industry Position

Table 133. Provepharm Life Solutions Company Profile and Main Business

Table 134. Provepharm Life Solutions Peptide CDMO Pharmaceutical Models, Specifications and Application

Table 135. Provepharm Life Solutions Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

Table 136. Provepharm Life Solutions Recent Developments

Table 137. Enzene Biosciences Company Information, Head Office, Market Area and Industry Position

Table 138. Enzene Biosciences Company Profile and Main Business

Table 139. Enzene Biosciences Peptide CDMO Pharmaceutical Models, Specifications and Application

Table 140. Enzene Biosciences Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

Table 141. Enzene Biosciences Recent Developments

Table 142. Piramal Pharma Company Information, Head Office, Market Area and Industry Position

Table 143. Piramal Pharma Company Profile and Main Business

Table 144. Piramal Pharma Peptide CDMO Pharmaceutical Models, Specifications and Application

Table 145. Piramal Pharma Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

Table 146. Piramal Pharma Recent Developments

List of Figure

Figure 1. Peptide CDMO Pharmaceutical Picture

Figure 2. Global Peptide CDMO Pharmaceutical Industry Market Size and Forecast (US$ million) & (2019-2030)

Figure 3. China Peptide CDMO Pharmaceutical Revenue and Forecast (US$ million) & (2019-2030)

Figure 4. 2019-2030 China Peptide CDMO Pharmaceutical Market Share of Global

Figure 5. Global Peptide CDMO Pharmaceutical Key Participants, Market Share, 2021 VS 2022 VS 2023

Figure 6. Global Peptide CDMO Pharmaceutical Market Share by Company, (Tier 1, Tier 2 and Tier 3), 2019-2024

Figure 7. China Peptide CDMO Pharmaceutical Key Participants, Market Share, 2021 VS 2022 VS 2023

Figure 8. China Peptide CDMO Pharmaceutical Revenue, Domestic VS Import Products, Proportion of China Local Players and Foreign Players, 2019-2024

Figure 9. Peptide CDMO Pharmaceutical Industry Chain

Figure 10. Liquid-phase Peptide Synthesis（LPPS）

Figure 11. Solid-phase Peptide Synthesis（SPPS）

Figure 12. Mixed Phase

Figure 13. By Type, Global Peptide CDMO Pharmaceutical Revenue, 2019-2030, US$ Million

Figure 14. By Type, Global Peptide CDMO Pharmaceutical Revenue Market Share, 2019-2030

Figure 15. Peptide Supplements

Figure 16. Peptide Vaccines

Figure 17. Others

Figure 18. By Application, Global Peptide CDMO Pharmaceutical Revenue, 2019-2030, US$ Million

Figure 19. By Application, Global Peptide CDMO Pharmaceutical Revenue Market Share, 2019-2030

Figure 20. By Region, Global Peptide CDMO Pharmaceutical Revenue Market Share, 2019-2030

Figure 21. North America Peptide CDMO Pharmaceutical Revenue & Forecasts, 2019-2030, US$ Million

Figure 22. By Country, North America Peptide CDMO Pharmaceutical Revenue Market Share, 2019-2024

Figure 23. Europe Peptide CDMO Pharmaceutical Revenue & Forecasts, 2019-2030, US$ Million

Figure 24. By Country, Europe Peptide CDMO Pharmaceutical Revenue Market Share, 2019-2024

Figure 25. Asia Pacific Peptide CDMO Pharmaceutical Revenue & Forecasts, 2019-2030, US$ Million

Figure 26. By Country/Region, Asia Pacific Peptide CDMO Pharmaceutical Revenue Market Share, 2019-2024

Figure 27. South America Peptide CDMO Pharmaceutical Revenue & Forecasts, 2019-2030, US$ Million

Figure 28. By Country, South America Peptide CDMO Pharmaceutical Revenue Market Share, 2019-2024

Figure 29. Middle East & Africa Peptide CDMO Pharmaceutical Revenue & Forecasts, 2019-2030, US$ Million

Figure 30. U.S. Peptide CDMO Pharmaceutical Revenue, 2019-2030, (US$ Million)

Figure 31. By Company, U.S. Peptide CDMO Pharmaceutical Market Share, 2019-2024

Figure 32. By Type, U.S. Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

Figure 33. By Application, U.S. Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

Figure 34. Europe Peptide CDMO Pharmaceutical Revenue, 2019-2030, (US$ Million)

Figure 35. By Company, Europe Peptide CDMO Pharmaceutical Market Share, 2019-2024

Figure 36. By Type, Europe Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

Figure 37. By Application, Europe Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

Figure 38. China Peptide CDMO Pharmaceutical Revenue, 2019-2030, (US$ Million)

Figure 39. By Company, China Peptide CDMO Pharmaceutical Market Share, 2019-2024

Figure 40. By Type, China Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

Figure 41. By Application, China Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

Figure 42. Japan Peptide CDMO Pharmaceutical Revenue, 2019-2030, (US$ Million)

Figure 43. By Company, Japan Peptide CDMO Pharmaceutical Market Share, 2019-2024

Figure 44. By Type, Japan Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

Figure 45. By Application, Japan Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

Figure 46. South Korea Peptide CDMO Pharmaceutical Revenue, 2019-2030, (US$ Million)

Figure 47. By Company, South Korea Peptide CDMO Pharmaceutical Market Share, 2019-2024

Figure 48. By Type, South Korea Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

Figure 49. By Application, South Korea Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

Figure 50. Southeast Asia Peptide CDMO Pharmaceutical Revenue, 2019-2030, (US$ Million)

Figure 51. By Company, Southeast Asia Peptide CDMO Pharmaceutical Market Share, 2019-2024

Figure 52. By Type, Southeast Asia Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

Figure 53. By Application, Southeast Asia Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

Figure 54. India Peptide CDMO Pharmaceutical Revenue, 2019-2030, (US$ Million)

Figure 55. By Company, India Peptide CDMO Pharmaceutical Market Share, 2019-2024

Figure 56. By Type, India Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

Figure 57. By Application, India Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

Figure 58. Middle East & Asia Peptide CDMO Pharmaceutical Revenue, 2019-2030, (US$ Million)

Figure 59. By Company, Middle East & Asia Peptide CDMO Pharmaceutical Market Share, 2019-2024

Figure 60. By Type, Middle East & Asia Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

Figure 61. By Application, Middle East & Asia Peptide CDMO Pharmaceutical Revenue Market Share, 2022 VS 2029

Figure 62. Research Methodology

Figure 63. Breakdown of Primary Interviews

Figure 64. Bottom-up Approaches

Figure 65. Top-down Approaches

Methodology/Research Approach

This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.

Research Programs/Design

Historical Data (2015-2019)	Industry Trends Competitive Landscape By Company Expansion Mergers and Acquisitions Market Segment by Type by Application By Regions/ Geography	Value Status and Outlook Value for Major Players Market Share Growth Rate Present Situation Analysis Value Market Share Growth Rate Present Situation Analysis
Influencing Factors	Market Environment Government Policy Technological Changes Market Risks	Market Drivers Growing Demand of Downstream Reduction in Cost
Market Forecast (2021-2026)	Overall Size by Type by Application By Regions/Geography	Key Data (Value) Market Share Growth Rate CAGR (2021-2026)

Market Size Estimation

Top-down and bottom-up approaches are used to validate the global Voluntary Carbon Offset market size market and estimate the market size for Company, regions segments, product segments and Application (end users).

The market estimations in this report are based on the marketed sale price of Voluntary Carbon Offset (excluding any discounts provided by the player, distributor, wholesaler or traders). The percentage splits, market share, and breakdowns of the product segments are derived on the basis of weights assigned to each of the segments on the basis of their utilization rate and average sale price. The regional splits of the overall Voluntary Carbon Offset market and its sub-segments are based on the percentage adoption or utilization of the given product in the respective region or country.

Major Company in the market is identified through secondary research and their market revenues determined through primary and secondary research. Secondary research included the research of the annual and financial reports of the top Company; whereas, primary research included extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs and marketing executives. The percentage splits, market share, Growth Rate and breakdowns of the product markets are determined through using secondary sources and verified through the primary sources.

All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Market Intellix and presented in this report

The following figure shows an illustrative representation of the overall market size estimation process used for this study.

Market Breakdown and Data Triangulation

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.

Data Source

Secondary Sources

Secondary sources include such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, etc. This research study involves the usage of widespread secondary sources, directories, databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), and TRADING ECONOMICS, and News Network, statista, Federal Reserve Economic Data, annual reports, BIS Statistics, ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and Hospitals study of the Voluntary Carbon Offset market. It was also used to obtain important information about the top companies, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.

Market Size	Segmental value Geographic Penetration Product Adoption Rate for Different market	Journals, Websites, and Press Releases Annual Reports and SEC Filings Company Websites and Press Releases Public and Paid Databases Market Intellix Data Repository
Market Position of Top Company	Product Financials Geographic value Mix Total Company value Business/Segmental value Mix
Qualitative Analysis	Influence Factors Market Potential Market Risks and Opportunities Industry Trends Geographical Features Government Policies	Company Websites and Press Releases Public and Paid Databases Annual Reports Industry Associations Market Intellix Data Repository

Primary Sources

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product Company (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end use (product buyers), and related key executives from various key companies and organizations operating in the global market.

Primary research was conducted to identify segmentation Type, product price range, product Application, key Company, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.

Key Executives Interviewed

Key Data Information from Primary Sources

Primary Sources	Parameters	Key Data
Market Segments(by Application, by Type)	Value by Type Status and Forecast Value by Application Value by Regions, Status and Forecast (2021-2026)	Value Market Share by Type Value Growth Rate by Type Value by Application Percentage and Growth Rate by Application Value Growth Rate and Market Share by Regions Market Size Status and Forecast (2021-2026)
Total Market	Overall Size, Status and Forecast	Market Size Status and Forecast (2021-2026)